Status:
COMPLETED
Transdermal Radiofrequency V ERASER Versus Polidocanol Sclerotherapy for Reticular Veins and Telangiectasias
Lead Sponsor:
Science Valley Research Institute
Conditions:
Varicose Veins Leg
Telangiectasias
Eligibility:
All Genders
Phase:
NA
Brief Summary
This study tested V Eraser, Transdermal radiofrequency versus polidocanol sclerotherapy for the treatment of reticular veins and telangiectasia of the legs
Detailed Description
Chronic Venous Disease causes symptoms such as pain, edema, and skin manifestations, including telangiectasias and varicose veins. Sclerotherapy with polidocanol is the gold standard treatment; howeve...
Eligibility Criteria
Inclusion
- Patients willing to sign informed consent
- Patients from 18 to 80 years old with CVD classified as CEAP clinical classes C1 to C5, but only telangiectasias and reticular veins not connected to larger varicosities
Exclusion
- Patients with great saphenous or small saphenous vein insufficiency.
- Patients with allergies to polidocanol
- Patients with contraindications to treat varicose veins
Key Trial Info
Start Date :
January 10 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 10 2025
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT06962813
Start Date
January 10 2023
End Date
April 10 2025
Last Update
May 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital São Luiz Gonzaga and Hospital da Irmandade Santa Casa de Misericórdia de São Paulo
São Paulo, São Paulo, Brazil, 02276-140